Triglycerides on the Rise: Should We Swap Seats on the Seesaw?

Topic: date: 07/01/2016 Featured Expert: Peter Libby, MD

Although we may be entering an era of waning cardiovascular risk attributable to LDL cholesterol, the recurrent event rate even with the best of current therapies remains unacceptably high...


Although we may be entering an era of waning cardiovascular risk attributable to LDL cholesterol, the recurrent event rate even with the best of current therapies remains unacceptably high. In his Keynote presentation, “Triglycerides on the Rise: Should We Swap Seats on the Seesaw?” Dr. Peter Libby will discuss the increasing prevalence of other cardiovascular risk factors, including triglycerides and specifically, the apolipoprotein constituent of many triglyceride-rich lipoproteins, apoC3. According to Dr. Libby, “We have a growing need for novel therapies that address the global shift in the risk factor profile we currently confront. Treatments that target triglyceride-rich lipoproteins, inflammation, diabetes, obesity, and other contributors to residual risk in the statin era now urgently require rigorous assessment in clinical trials.”

BACK